Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit for more info.

Dr. Joel Neal summarizes preliminary results of the SELECT trial of adjuvant Tarceva (erlotinib) for patients with resected EGFR mutation-positive early stage non-small cell lung cancer. 

Direct download: GRACEcast-116_Lung-Audio_ASCO_2012_Neal_8.mp3
Category:Lung-Cancer-Audio -- posted at: 4:11pm PDT